Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Swedish Orphan Biovitrum    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM

(SOBI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Stockholm
07/01/2020 07/02/2020 07/03/2020 07/06/2020 07/07/2020 Date
216.1(c) 218(c) 218.1(c) 216.9(c) 217.2(c) Last
639 238 334 741 298 715 401 811 366 085 Volume
+0.42% +0.88% +0.05% -0.55% +0.14% Change
More quotes
Financials
Sales 2020 16 144 M 1 747 M 1 747 M
Net income 2020 3 267 M 353 M 353 M
Net Debt 2020 10 177 M 1 101 M 1 101 M
P/E ratio 2020 19,7x
Yield 2020 -
Sales 2021 17 444 M 1 887 M 1 887 M
Net income 2021 3 939 M 426 M 426 M
Net Debt 2021 4 740 M 513 M 513 M
P/E ratio 2021 16,3x
Yield 2021 -
Capitalization 63 834 M 6 888 M 6 906 M
EV / Sales 2020 4,58x
EV / Sales 2021 3,93x
Nbr of Employees 1 400
Free-Float 61,9%
More Financials
Company
Swedish Orphan Biovitrum is specialized in the development, manufacturing and marketing of therapeutic products intended for the treatment of rare diseases (hemophilia, inflammatory and autoimmune illnesses, hereditary metabolic diseases, etc.). The turnover per source of income can be broken down as follows: - sales of products (80.5%); - royalties (14.7%); - sales of sub-contracted manufactured products... 
More about the company
Surperformance© ratings of Swedish Orphan Biovitrum
Trading Rating : Investor Rating :
More Ratings
Latest news on SWEDISH ORPHAN BIOVITRUM
07/06SWEDISH ORPHAN BIOVITRUM : Invitation - Presentation of Sobi's Q2 2020 results
AQ
06/26SWEDISH ORPHAN BIOVITRUM : Successful Elocta bid means increased access for peop..
AQ
06/14SWEDISH ORPHAN BIOVITRUM : Sobi and Sanofi donate up to 500 million additional I..
AQ
05/13SWEDISH ORPHAN BIOVITRUM : Bulletin from Swedish Orphan Biovitrum's ("Sobi") Ann..
AQ
05/13SWEDISH ORPHAN BIOVITRUM : Proxy Statments
CO
05/07SWEDISH ORPHAN BIOVITRUM : Results from pivotal phase 2/3 study of emapalumab in..
AQ
04/29SWEDISH ORPHAN BIOVITRUM : Sobi publishes report for the first quarter 2020
AQ
04/29SWEDISH ORPHAN BIOVITRUM : Slide show Q1 results
CO
04/23SWEDISH ORPHAN BIOVITRUM : Invitation, Presentation of Sobi's Q1 2020 results
AQ
04/22SWEDISH ORPHAN BIOVITRUM : Invitation - Presentation of Sobi's Q1 2020 results
AQ
04/22SWEDISH ORPHAN BIOVITRUM : Sobi™ affiliate Florio GmbH, launches a new dig..
AQ
04/20SWEDISH ORPHAN BIOVITRUM : Sobi offers advance voting at the 2020 annual general..
AQ
04/17SWEDISH ORPHAN BIOVITRUM : New data shows varied state of haemophilia treatment ..
AQ
04/14EUROPE : European shares rise on China trade data, easing coronavirus worries
RE
04/13SWEDISH ORPHAN BIOVITRUM : Sobi sees strong revenue and EBITA growth in the firs..
AQ
More news
News in other languages on SWEDISH ORPHAN BIOVITRUM
07/06SWEDISH ORPHAN BIOVITRUM : Invitation - Presentation of Sobi's Q2 2020 results
06/26SWEDISH ORPHAN BIOVITRUM : Successful Elocta bid means increased access for peop..
06/19AVIS D'ANALYSTES DU JOUR : Colruyt, Delta Plus, EDF, Flutter, Fnac Darty, Geberi..
06/14SWEDISH ORPHAN BIOVITRUM : Sobi and Sanofi donate up to 500 million additional I..
05/13SWEDISH ORPHAN BIOVITRUM : Bulletin from Swedish Orphan Biovitrum's ("Sobi") Ann..
More news
Chart SWEDISH ORPHAN BIOVITRUM
Duration : Period :
Swedish Orphan Biovitrum Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SWEDISH ORPHAN BIOVITRUM
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 233,00 SEK
Last Close Price 216,90 SEK
Spread / Highest target 23,1%
Spread / Average Target 7,42%
Spread / Lowest Target -5,49%
EPS Revisions
Managers
NameTitle
Guido Oelkers President & Chief Executive Officer
Sven Håkan Björklund Chairman
Henrik Stenqvist Chief Financial Officer
Milan Zdravkovic Chief Medical Officer, Head-Research & Development
Anne Marie de Jonge Schuermans Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
SWEDISH ORPHAN BIOVITRUM40.39%6 888
JOHNSON & JOHNSON-3.36%376 694
ROCHE HOLDING AG5.88%300 494
MERCK & CO., INC.-12.50%200 868
NOVARTIS AG-9.17%195 408
PFIZER, INC.-11.92%191 697